Organic Active Ingredients TRIZ Cases

Selective 7-azaindole serotonin agonists target 5-HT2A while limiting hallucinogenic effects and 5-HT2B-linked cardiotoxicity.

P-gp efflux and tuned molecular properties help these NLRP3 inhibitor compounds limit brain exposure while preserving peripheral efficacy.

A lipid-encapsulated famotidine layer separates from antacid and moisture to preserve stability while delivering rapid heartburn relief.

Pan-RAF inhibitor scaffolds broaden RAF family targeting to improve efficacy in colorectal and other RAF-driven cancers beyond B-RAF selective therapy.

Amino-modified hyaluronic acid cross-linked with genipin gels within 1 hour at 37°C, enabling biocompatible in-situ medical use.

Engineered RNA and hybrid scaffolds improve ADAR recruitment to target RNA, boosting point-mutation editing efficiency and specificity.

Wet-granulated orodispersible estetrol units dissolve quickly in the mouth to bypass first-pass liver metabolism and improve absorption.

Inclusion complexes with sulfoalkyl ether cyclodextrin help poorly soluble silymarin dissolve better and improve topical and oral bioavailability.

Novel heterocyclic MIF inhibitors improve treatment effectiveness by selectively reducing inflammation and tumor progression in MIF-mediated diseases.

Glutathione-activated PBD prodrug antibody conjugates improve tumor cell killing while reducing cardiotoxicity and tissue necrosis.

Nitrosation followed by thiourea dioxide reduction improves aminoindole yield and purity while avoiding harmful by-products.

Herbal terpenoids from Antrodia camphorata and Anisomeles indica inhibit mast cell tumor growth and induce apoptosis with fewer side effects.

Ultra-sensitive free LIGHT detection separates active cytokine from bound forms, enabling anti-LIGHT treatment selection in ARDS and Crohn's disease.

Adjusted migalastat dosing maintains Fabry disease treatment during pregnancy while reducing fetal risk and supporting normal birth outcomes.

Defined GLP-1 agonist crystal forms balance dissolution and stability, enabling more consistent storage, crystallization, and oral drug production.

Phospholipids with sucrose improve the bioavailability and stability of a 1'-cyano carba-nucleoside antiviral while preserving activity.

A multi-ingredient micronutrient composition supports ECM repair while lowering IL-6 and MMP13 to improve joint health in chronic arthritis.

A quinazolinone BRAF inhibitor case showing how structural changes preserve BRAFV600E potency while reducing paradoxical MAPK activation.

Novel phosphorthiamine compounds use acyl-modified thiamine structures to inhibit Aβ40 and Aβ42 and support Alzheimer's disease progression control.

Fluoroallylamine triazolone derivatives selectively inhibit VAP-1 to reduce inflammation and fibrosis in NASH treatment.

A whey, leucine, and omega-3 composition helps counter cancer cachexia by supporting muscle function, daily activity, and therapy compliance.

Inorganic pH regulation keeps liquid cytisine stable for oral spray or mist use, improving compliance without tablets or water.

Hydroxypyrrolidine arylsulfonamides selectively block Nav1.7 channels to treat pain, cough, and itch with fewer off-target side effects.

A pyranochromene derivative targets chondrocyte metabolism, inflammation, and apoptosis to treat osteoarthritis with fewer side effects.

Piperazine-substituted indazole compounds improve PARG specificity, solubility, and cell permeability to help address PARP inhibitor resistance.

Room-temperature hypochlorite oxidation raises remimazolam besylate yield while reducing impurities, cost, and low-temperature process demands.

Carboxylic acids in the adhesive solubilize buprenorphine, enabling a smaller weekly patch with less skin irritation and drug waste.

Selective quinazoline HDAC6 inhibitors improve tubulin hyperacetylation while limiting off-target HDAC effects in neuropathy and fibrosis treatment.

Novel imidazole-pyrazole derivatives target drug-resistant Acinetobacter baumannii, expanding treatment options for hard-to-manage infections.

Local hyaluronic acid hexadecyl amide hydrogel boosts osteoblast formation and bone mineralization in fragile fractures while staying at the site.

Salt formation with hydrochloride or mesylate improves bile acid derivative solubility, stability, and FXR agonist activity for liver disease drugs.

Breakpoint mapping within 1.3 Mb of an oncogene TSS improves IGH translocation detection and helps guide targeted cancer therapy.

Alcoholysis and reduction improve selectivity, reproducibility, and scale-up for lower-cost production of high-purity MOR agonists.

Cyclic phosphate nucleoside derivatives act as prodrugs to inhibit HBV replication while improving liver disease treatment efficacy and safety.

Multiple crystalline forms are characterized by XRPD and thermal analysis to balance bioavailability, stability, and formulation reliability.

A Trop-2-targeted antibody-drug conjugate improves tumor cell targeting and killing while reducing adverse reactions in refractory solid tumors.

Novel cyclic triazole compounds improve CNS and peripheral anti-inflammatory activity while balancing bioavailability, permeability, and safety.

New 2-substituted naphthimidazolone compounds mitigate mitochondrial dysfunction and oxidative stress to strongly suppress cell death.

By inhibiting bradykinin receptor binding, these NSAID-linked amino acid derivatives suppress tumor growth and invasion with reduced toxicity.

Compounds that restore NAD by limiting consumption or boosting synthesis help protect neurons from misfolded protein toxicity in neurodegeneration.

By blocking β-TrCP-mediated NRF2 degradation, these compounds treat fatty liver inflammation and oxidative stress without excess NRF2 activation.

Suprachoroidal microneedle delivery of plasma kallikrein inhibitors improves posterior eye retention while reducing repeat injections and systemic exposure.

Blood NGAL and NGAL-MMP9 markers help identify CSCR risk and distinguish acute from chronic cases when imaging is inconclusive.

By removing ceruloplasmin with specific antibodies, this case enables direct free copper measurement and more accurate diagnosis of Wilson disease.

Acellular MSC secretome combines exosomes, growth factors, and biomolecules to inhibit viral replication while regulating inflammation.

PEG12KL4 forms stable mRNA nano-complexes that dry into inhalable powder with good aerosol dispersibility and deep lung transfection.

Novel fused heterocyclic dicyanides inhibit tau aggregation and hyperphosphorylation while avoiding cytotoxicity in neurodegenerative disease therapy.

Group IVA phospholipase A2 inhibition reprograms T cell lipid metabolism to block senescence and improve tumor immunotherapy efficacy.

Limited 0.15, 0.3, and 0.5 mL markings let users identify standard epinephrine doses faster and inject accurately during anaphylaxis.

Selective adamantane derivatives inhibit FAK and Pyk2 while sparing insulin receptor function, reducing cytotoxicity in cancer treatment.

Structured guide RNAs improve ADAR editing specificity and on-target SNCA knockdown while limiting off-target RNA edits.

DHB helps protect red blood cells from exercise-induced ROS, supporting AMPK balance, antioxidant capacity, endurance, and fatigue reduction.

Direct leucine delivery offers a broad treatment approach for lysosomal storage disorders and neurodegeneration while improving mobility and cognition.

Cobinamide neutralizes ROS and RNS faster than cobalamin, reducing oxidative stress, fibrosis, and biomolecular damage in diabetes.

Blocking ENT1 raises extracellular adenosine to activate A1 receptor signaling, relieving inflammatory and neuropathic pain with fewer side effects.

Dual-site CK2α inhibitors bind the ATP pocket and αD site to improve kinase selectivity while maintaining potent enzyme inhibition.

Puromycin targets GNAQ R183Q or Q209L mutant cells to inhibit proliferation and slow vascular malformation progression.

Specific lipid ratios in nanoparticles deliver genome editing molecules into hematopoietic stem cells while reducing electroporation burden and toxicity.

Combining pexidartinib with nintedanib helps inhibit pulmonary fibrosis progression and improves survival beyond single-drug treatment.

A 5-HT4 receptor agonist improves memory in menopause, schizophrenia, and chemobrain models without hormone replacement risks.

Replacing Axitinib’s aromatic ring with a bicyclo[2.1.1]hexane scaffold boosts cancer cell activity while using photocycloaddition for stereocontrol.

N-acetylcysteine stabilizes sulfite-free adrenalin with an antidepressant to improve rapid bioavailability and plasma exposure in shock treatment.

Using ApoE-containing rHDL nanoparticles, this case shows BBB crossing and cholesterol efflux to kill glioblastoma and pancreatic cancer cells.

Separating binder into the solid filler and spraying a low-viscosity control solution prevents lumping and keeps pouch filler particles uniform.

Controlled spray coating at 35-45°C improves testosterone dose uniformity, taste, and immediate oral release in dual drug delivery tablets.

A lyophilized disodium 5,10-methylene-THF composition uses citrate and sulfate to improve solubility, purity, and oxidation stability.

A benzene-ring compound library improves P2X4 inhibition selectivity while lowering toxicity and supporting metabolic stability for chronic cough treatment.

Controlled cariprazine hydrochloride particle size improves dissolution and stability in a solid oral composition without complex aqueous formulation.

Functionalized polystyrene microspheres adsorb and stabilize mRNA at room temperature, avoiding cryogenic storage, added protectants, and biosafety risks.

Defined framework back mutations restore affinity and stability in humanized anti-CLDN6 antibodies while preserving selectivity for tumor targeting.

Long-term MS treatment with ofatumumab maintains serum IgG during B-cell depletion, helping reduce infection risk.

Aminonorbornane derivatives selectively inhibit BTK(C481S), overcoming resistance that limits existing BTK therapies in cancer and autoimmune disease.

A staged acid reaction in water-immiscible solvent replaces chromatography and lyophilization to isolate high-purity Isavuconazonium sulfate.

A novel S1P receptor modulator approach targets the lack of approved ME/CFS therapies by relieving fatigue and improving quality of life.

Sterile filtered media exchange lets closed-system TIL expansion cut contamination risk, shorten manufacturing, and support therapeutic production.

A pH-controlled Nebivolol oral liquid uses solubilizers and sweeteners to improve solubility, stability, and dosing for children and elderly patients.

Combining betaine hydrochloride and phytase raises AME synergistically, cutting feed input costs while maintaining growth performance.

A water-soluble polyaryl carboxylic fullerene derivative addresses the lack of effective COVID-19 antivirals by inhibiting SARS-CoV-2 infection in cells.

Liposome-encapsulated peptides and actives help clear post-filler bruising faster by improving macrophage function and reducing inflammation.

Gamma-secretase inhibition preserves surface BCMA and lowers soluble BCMA, improving belantamab mafodotin efficacy with less ocular toxicity.

Bifunctional compounds link an IRAK4 binder to a ligase harness moiety to drive ubiquitination and proteasomal degradation for disease treatment.

An acellular MSC secretome with exosomes and biomolecules inhibits viral infection and replication while reducing cytokine storm and ARDS.

Local tumor delivery of anti-CD40 with systemic immunotherapy boosts solid tumor response while reducing cytokine release syndrome.

Selective crystallization of the trans-isomer from a cis/trans mixture boosts pyrimidino-diazepine derivative yield and simplifies purification.

Direct pulmonary T3 delivery counters D3-driven fluid buildup, boosting alveolar clearance and oxygen diffusion in ARDS-related edema.

Structural changes to QS-21 and QS-7 analogues boost adjuvant activity while lowering toxicity and easing pure adjuvant production.

CRF1 antagonists reduce TART and OART size while lowering ACTH, 17OHP, and A4 in CAH without high-dose steroid burden.

Targeted CALHM2 inhibition lowers ROS and ischemia-reperfusion injury while protecting mitochondrial health and limiting organ damage.

Thyroid hormones and Triac boost ζ-globin expression, offering a lower-burden drug approach for sickle-cell disease.

Neurosteroids enhance autophagic flux to protect retinal ganglion cells from pressure-induced glaucoma injury when pressure control alone falls short.

DPEP-1 binding agents target endothelial inflammation sites to block leukocyte recruitment while reducing side effects and acute kidney injury risk.

Conformationally constrained ionizable lipids redirect lipid nanoparticle trafficking to T cells while lowering liver and spleen clearance at lower doses.

Multiple polymorphic forms of a 3CL protease inhibitor improve solid-state stability and pharmaceutical compatibility despite added manufacturing complexity.

Controlled crystallization turns unstable amorphous NMNH disodium salt into low-hygroscopic polymorphs with better flow, stability, and purity.

Double-stranded RNAi agents silence PNPLA3 mRNA to reduce triglyceride buildup and slow NAFLD progression toward NASH and cirrhosis.

Selective thioxo pyrrolopyrimidinone MPO inhibitors address heart failure fibrosis while limiting off-target peroxidase activity and CNS exposure.

Ionic surfactants and water-soluble polymers prevent nanoparticle aggregation during drying, preserving redispersion and dissolution.

Unshielded RN7SL1 RNA levels reveal aggressive cancer behavior and help predict immunotherapy response for personalized treatment.

Group I intron self-splicing and IRES elements enable circular RNA with longer half-life and sustained protein expression in eukaryotic cells.

Gene and protein biomarker analysis enables earlier memory dysfunction assessment, Alzheimer's risk prediction, and personalized drug matching.

Liposomes with phospholipids, sterol, and maltodextrin help brilaroxazine cross the skin barrier and sustain topical psoriasis treatment.

Controlling plastic container surface area to volume ratio limits norepinephrine oxidation impurities and extends storage stability.

Controlled crystallization creates stable, high-purity ORL-1 modulator polymorphs with XRPD-defined forms for safer, more effective sleep disorder treatment.

Selective ASK1 inhibitor delivery raises liver and kidney exposure above plasma while supporting oral dosing or rapid injection for organ disease treatment.

ARID1A mutation stratification guides EZH2 inhibitor therapy to improve growth inhibition and response in bladder and endometrial cancers.

Partial visual cycle inhibition with 4-phenylpiperidines lowers toxic bisretinoid buildup in retinal pigment epithelium for dry AMD.

CBG alters tumor cytokine signaling to reduce regulatory myeloid cells and improve immune checkpoint inhibitor efficacy in cancer.

Nanobubbles improve antiparasitic agent dispersion, solubility, and parasite contact to achieve more uniform ectoparasite control in fish farming.

Targeting BSN-tau binding with shRNA or antibodies reduces tau spreading and neurofibrillary tangle pathology in neurodegenerative disorders.

A pre-primed intranasal nalmefene product enables needleless overdose treatment with rapid plasma exposure and longer action in remote settings.

Controlled crystallization stabilizes compound A and its salts while preserving bioavailability for diabetes treatment.

Dispersed microneedle particles create removable microchannels in tissue, improving bioactive delivery while limiting tissue damage.

Anhydrous lipid nanoparticles use ionizable cationic lipids to protect RNA, extend circulation, and improve intracellular uptake.

Fused heteroaryl scaffolds improve CaMKII selectivity while supporting oral and chronic treatment of arrhythmia and heart failure.

Small heterocyclic compounds block C. difficile toxin glucosylation, suppress pathology, and preserve normal intestinal flora.

An euglobulin-plasmin assay measures defibrotide biological activity more precisely and reproducibly, supporting standardized formulations.

A maleate crystal form improves solubility, lowers hygroscopicity, and supports stable, flowable drug production through controlled crystallization.

Fungal protein and nucleic acid biomarkers enable earlier, more reliable Valley Fever diagnosis than host antibody tests that miss spherule antigens.

Multiparticulate rosuvastatin pellets use osmotic release modifiers and stabilizers to ease administration in dysphagia while staying stable.

Aldoxorubicin is paired with cetuximab and haNK immune components to cut MDSC suppression and improve tumor response in hypoxic microenvironments.

SMARCA4 and SWI/SNF alteration screening enables earlier SCCOHT detection and guides targeted treatment beyond chemotherapy resistance.

Selective TβRII antagonist fusion proteins target fibrotic TGFβ signaling in systemic sclerosis to slow FVC decline and improve lung function.

HiT-StARTS maps selective RNA motif-small molecule binding to cut 2DCS processing time and identify miR-18a inhibitors in cancer cells.

High-load cellulose oral films use controlled active-agent solubility and drying to keep distribution uniform while preserving fast disintegration.

Phytogenic feed additives with Quillaja, capsaicin, and essential oils help prevent white feces syndrome and improve shrimp survival and growth.

Mesylate salt forms of triazolopyrazine improve solubility and stability while preserving c-Met kinase inhibition for therapy.

Azabenzimidazole M3 PAMs boost receptor signaling through allosteric binding, supporting therapy for underactive bladder and related disorders.

A new azacycle compound class activates TRPM8 to deliver longer-lasting cooling on skin and mucosa at low concentrations.

A testosterone dodecanoate oral composition improves bioavailability in end-stage disease while lowering cardiovascular and prostate risks.

High-pressure jet injection delivers testosterone to the desired depth with less leak-back, less skin exposure, and steadier blood levels.

CRISPRa reactivates silenced STING in low-expression tumors, restoring response to STING agonists and strengthening anti-tumor immunity.

Delayed-release vitamins B2, C, and D target the large intestine to selectively increase B. lactis and improve gut health.

Targeted RNAi silences KLKB1, F12, and KNG1 to lower bradykinin activity and help prevent hereditary angioedema attacks.

Glycerol carries cannabinoid ions that convert at neutral pH and absorb through epithelium, reducing cytochrome P450 oxidation.

Amino lipid compounds in lipid nanoparticles improve nucleic acid entry into cells by better matching particle properties to cellular structures.

Tailored atogepant dosing manages CYP3A4 and OATP interactions while maintaining migraine prophylaxis in renal or hepatic impairment.

Optimized antibody-SN-38 dosing and cleavable linkers improve tumor targeting while reducing systemic toxicity in resistant cancers.

A cell-free and exosomal miRNA panel improves early PDAC detection where CA19-9 misses patients, including Lewis antigen-negative cases.

Free-form arginine, histidine, and sodium in freshwater feed help smolts maintain intake, growth, seawater readiness, and lower cataract severity.

Ultrasonically molded thermoplastic wraps confine bone graft therapeutics at defect sites while limiting tissue encroachment and ectopic bone formation.

Low-dose sulfoquinovosylacylpropanediol given just before irradiation boosts tumor radiosensitivity, improving volume reduction with limited toxicity.

Controlled oral minoxidil release maintains therapeutic serum levels over time, reducing side effects and frequent dosing in hair loss treatment.

Electroporation loads nucleic acids or proteins into extracellular vesicles, improving target-cell delivery while preserving biocompatibility.

Fast-dispersing riluzole tablets improve bioavailability, ease swallowing, and reduce first-pass liver metabolism in ALS treatment.

By blocking GPX4-dependent lipid peroxidase activity, these compounds trigger ferroptosis to kill therapy-resistant cancer cells.

Activin pathway inhibitors suppress Treg function and proliferation, helping anti-tumor vaccines overcome immune suppression and shrink tumors.

By blocking TGF-β1/Smad, STAT3, and NF-κB signaling, ACT004 suppresses EMT, reduces ECM deposition, and helps preserve kidney function.

Polymer suspending agents and an oxygen-barrier pouch keep levodopa-carbidopa intestinal gel stable, limiting sedimentation and oxidation.

Cocrystal forms of fasoracetam raise melting point and improve stability, making tableting, packaging, and storage more robust.

Novel pyrimidine-fused compounds selectively inhibit KRAS G12 mutations while improving pharmacodynamic performance and reducing off-target effects.

Adding PEG to Py-C12 fixation compositions reduces fluid leakage and skin-barrier permeability while preserving antimicrobial efficacy.

Electrospinning traps poorly soluble bioactives in ultrafine fibres for controlled mucosal or dermal release without invasive dosing.

Poorly absorbed bergamot flavanone glycosides are complexed with phospholipids and processed into powder for lower oral doses.

Existing inhibitors have pharmacokinetic limits for chronic use; metabolizable prodrugs improve absorption and half-life for more consistent dosing.

Liquid-liquid extraction and cartridge fractionation remove chlorophyll while recovering characterized polar lipids and Omega-3-rich algal oil.

An enteric-coated tablet delays release until the small intestine, helping regulate calcium signaling during ryanodine receptor treatment.

Replace painful intramuscular injections for acute agitation with a nasal spray that delivers olanzapine through the mucosa within 20 minutes.

Genetic testing for PNPLA3 I148M and functional HSD17B13 identifies candidates before liver disease progresses.

Guide RNAs and deaminase-Cas9 nickases target the MYH7 R403Q mutation to address cardiomyopathy at its genetic cause.

Modified oligonucleotides reduce Ataxin-2 mRNA and protein expression, improving motor function and limiting motor neuron loss.

Formula I compounds address limited neurodegenerative treatment efficacy by seeking good brain exposure and therapeutic benefit.

The staged process combines reductive alkylation with stable-radical oxidation to deliver methylene blue containing less than 0.7 ppm N-nitroso-Azure B.

Combining flavonoids such as luteolin with xanthones such as gamma-mangostin targets inflammatory cytokines and skin symptoms.

PI3K inhibitors target gain-of-function PIK3CA signaling to suppress abnormal proliferation in difficult-to-treat venous malformations.

Because cerebral stroke treatments remain inadequate, this case uses circ-Magi1 knockdown to support prevention and treatment.

Alcohol-free water-glycerol formulation and multi-barrier containers limit T4 conversion to T3, supporting stable dosing during storage.

Beta-glucan, avenanthramides, and phenolics are administered in powders or foods to reduce inflammatory biomarkers and systemic chronic inflammation.

Selective compounds target GIRK1/2 or GIRK1/4 channels to separate neuronal therapy from cardiac side effects.

Inositol phosphates inhibit hydroxyapatite crystal formation and growth to slow coronary, aortic, and valve calcification.

Automated powered injection helps patients self-administer hazardous agents while limiting accidental exposure and improving delivery consistency.

Guide RNA and Cas effector proteins target DUX4 for nucleotide editing, while AAV vectors deliver the approach to muscle cells for FSHD treatment.

CRISPR/Cas9, siRNA, and overexpression adjust IFNAR2 isoforms to improve IFN sensitivity while reducing off-target toxicity.

Elevating synaptic glycine triggers glycine-induced NMDA receptor internalization, providing neuroprotection and reducing stroke severity without bleeding risk.

Low DHA yields in crops are addressed by modular desaturation and elongation enzymes that raise plant-lipid DHA toward fish-oil levels.

Controlled glucose and sorbitol levels help cellulose-based orally disintegrating tablets retain hardness during storage while limiting core residue.

Traditional delivery lacks effective immune targeting; engineered exosomes carry immunomodulators to boost anti-tumor responses or suppress inappropriate activity.

Befiradol activates selective 5-HT1A receptors to reduce L-DOPA-induced dyskinesia while maintaining or improving parkinsonian symptoms.

Sequence variation can undermine ISS-ODN efficacy; GM-090 fragments stimulate TLR9 and cytokines for immune regulation.

Hydrolysis, nitrile reduction, and final amide coupling form a scalable route to high-purity E9 for clinical and commercial supply.

Gradual selexipag dose escalation transitions PAH patients from non-selexipag agents while balancing treatment efficacy and tolerability.

Amphotericin B crystal particles pair with lipids to form ion channels, raising airway pH and bicarbonate secretion for Class I cystic fibrosis.

Nav1.7 inhibitors in this case target pain and pruritus while selective heteroaromatic amide structures reduce unwanted Nav1.5 cardiac effects.

Low-solubility, lipophilic benzamides concentrate JAK inhibition in the gastrointestinal tract, helping limit systemic exposure and side effects.

Oxidative stress and mitochondrial dysfunction drive retinal damage; these compounds protect RPE cells, preserve viability, and support AMD therapy.

Cholic acid 7-sulfate derivatives target TGR5 to trigger GLP-1 secretion, lower blood glucose, and improve insulin sensitivity.

Systematic acid screening produces OAD2 crystalline salts with improved stability and hygroscopicity for GLP-1 therapy.

Omega-3 fatty acids face oxidation during food production and storage; low-molecular-weight protein shells protect them while limiting surface free fat.

Formula I compounds are designed to inhibit TDP-43 aggregation and toxicity, addressing limited relief in ALS and FTD therapies.

Hormone receptor, HER2, and BRCA testing directs PARP or CDK4/6 inhibitor selection in a workflow designed to address breast cancer relapse.

Position-specific substituents tune 5-HT2A over 5-HT2B activity, aiming for therapeutic effects without hallucination or cardiotoxicity.

HSP90 inhibition targets IL-1β, NLRP3 inflammasome, and other cytokines to reduce HS abscesses and nodules.

STAT3-targeting siRNA addresses tumor and microenvironment drivers of drug resistance, while PD-L1 inhibition reduces tumor volume and re-growth.

Benzothiazole derivatives selectively inhibit JAK2, addressing poor conventional-therapy response in hematologic neoplasms and lymphomas.

Existing cessation products often have low success rates and adverse reactions; periodic cefdinir aims to reduce tobacco cravings with minimal side effects.

USP28 or USP25 targeting ligands pair with protein-targeting ligands to remove ubiquitin, limit proteasomal degradation, and restore function.

Cell-permeable pyridone carboxamides reach intracellular HPK-1 to enhance T-cell priming and anti-tumor efficacy.

A mucoadhesive polymer film keeps psilocybin on buccal tissue for prolonged release while bypassing first-pass metabolism.

Controlled-release polymers support oral dengue prevention and treatment in fed or fasted humans while reducing food-related exposure variability.

Replacing high-GWP propellants, the formulation uses HFA152a or HFO1234ze and alcohol to maintain consistent inhaler delivery after storage.

Ionizable lipid nanoparticles carry CRISPR components to lung cells for CFTR repair, addressing viral-vector immunogenicity and integration concerns.